When was Angiomax (bivalirudin) first patented?
Angiomax’s active ingredient is bivalirudin. The specific “Angiomax” product name is not tied to a single patent date; instead, approval and commercial availability depend on the original bivalirudin (and related) patent filings and their priority dates.
Which patent filings likely matter for “when it was patented”?
To answer “when was Angiomax patented” precisely, you typically need the earliest priority date for the core bivalirudin invention (the compound) plus any additional patents covering formulation, use, or manufacturing. Those can have different filing years and expiration timelines, even if the marketed drug is the same.
What I need to give an exact patent date
I can’t determine the exact patent date from the question alone. If you share either of these, I can pinpoint the date accurately:
- the patent number (or a link), or
- the country (e.g., US vs. EP) and whether you mean the first patent on bivalirudin or the first patent on the Angiomax-branded drug/product.
Quick way to proceed
If you tell me “US patent” (or another jurisdiction) and whether you want “earliest bivalirudin patent” versus “first Angiomax-related patent,” I’ll return the exact year (and priority/filing date) you’re looking for.